- Home
- YQ vs NRXS Comparison
YQ vs NRXS Comparison
Compare YQ & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- NRXS
- Stock Information
- Founded
- YQ 2012
- NRXS 2011
- Country
- YQ China
- NRXS United States
- Employees
- YQ N/A
- NRXS N/A
- Industry
- YQ Other Consumer Services
- NRXS
- Sector
- YQ Real Estate
- NRXS
- Exchange
- YQ Nasdaq
- NRXS Nasdaq
- Market Cap
- YQ 11.7M
- NRXS 12.5M
- IPO Year
- YQ 2020
- NRXS 2023
- Fundamental
- Price
- YQ $1.79
- NRXS $2.40
- Analyst Decision
- YQ
- NRXS
- Analyst Count
- YQ 0
- NRXS 0
- Target Price
- YQ N/A
- NRXS N/A
- AVG Volume (30 Days)
- YQ 51.2K
- NRXS 36.9K
- Earning Date
- YQ 06-04-2025
- NRXS 05-21-2025
- Dividend Yield
- YQ N/A
- NRXS N/A
- EPS Growth
- YQ N/A
- NRXS N/A
- EPS
- YQ N/A
- NRXS N/A
- Revenue
- YQ $25,922,648.00
- NRXS $2,685,925.00
- Revenue This Year
- YQ N/A
- NRXS $138,883.78
- Revenue Next Year
- YQ N/A
- NRXS $118.59
- P/E Ratio
- YQ N/A
- NRXS N/A
- Revenue Growth
- YQ 10.68
- NRXS 9.18
- 52 Week Low
- YQ $1.26
- NRXS $1.33
- 52 Week High
- YQ $3.19
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- YQ 52.34
- NRXS 65.87
- Support Level
- YQ $1.51
- NRXS $1.33
- Resistance Level
- YQ $1.98
- NRXS $2.09
- Average True Range (ATR)
- YQ 0.26
- NRXS 0.36
- MACD
- YQ 0.03
- NRXS 0.06
- Stochastic Oscillator
- YQ 51.35
- NRXS 90.95
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers to assist students, teachers, schoolmasters, and educational authorities across China to achieve data-driven teaching, learning, and assessment. Geographically group operates in China.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).